WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
Generado por agente de IAMarcus Lee
martes, 18 de febrero de 2025, 4:10 am ET1 min de lectura
BIO--

Shanghai, February 18, 2025 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it has been awarded a Platinum Medal by EcoVadis Sustainability Rating for the second consecutive year. This recognition highlights WuXi Bio's commitment to sustainable development and responsible business practices.
EcoVadis is a leading global sustainability intelligence platform for global supply chains, evaluating companies based on their environmental, social, and governance performance. The Platinum Medal is the highest level of recognition, awarded to companies that demonstrate outstanding sustainability practices and a strong commitment to continuous improvement.
WuXi Biologics' Platinum Medal recognition is a testament to its dedication to sustainable development, as it ranked in the top 1% of over 150,000 companies evaluated worldwide. The company's commitment to ESG (Environmental, Social, and Governance) principles is deeply rooted in its business strategy, and it continues to strive for excellence in all aspects of its operations.

As a leader in Green CRDMO, WuXi Biologics is committed to driving innovation for a healthier future. The company's green biologics solutions, such as WuXiBody™ dual-specific antibody technology, WuXiUI™ super-high-yield batch culture technology, and WuXiUP™ continuous bioreactor technology, help reduce resource consumption and carbon footprint, contributing to a more sustainable future.
WuXi Biologics' commitment to sustainability has been recognized by major ESG rating agencies. The company has been granted a "AAA" rating from MSCI ESG Ratings, awarded the distinguished Platinum Medal by EcoVadis, and recognized as an Industry and Regional Top-Rated Company by Sustainalytics. Additionally, WuXi Bio has been named to the CDP Water Security “A list” and awarded an “A-” CDP Climate Change score, demonstrating its strong performance in environmental stewardship.

In conclusion, WuXi Biologics' Platinum Medal recognition by EcoVadis for the second consecutive year underscores the company's unwavering commitment to sustainable development and responsible business practices. As a leader in Green CRDMO, WuXi Bio continues to drive innovation and contribute to a healthier, more sustainable future for all stakeholders.
MSCI--

Shanghai, February 18, 2025 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it has been awarded a Platinum Medal by EcoVadis Sustainability Rating for the second consecutive year. This recognition highlights WuXi Bio's commitment to sustainable development and responsible business practices.
EcoVadis is a leading global sustainability intelligence platform for global supply chains, evaluating companies based on their environmental, social, and governance performance. The Platinum Medal is the highest level of recognition, awarded to companies that demonstrate outstanding sustainability practices and a strong commitment to continuous improvement.
WuXi Biologics' Platinum Medal recognition is a testament to its dedication to sustainable development, as it ranked in the top 1% of over 150,000 companies evaluated worldwide. The company's commitment to ESG (Environmental, Social, and Governance) principles is deeply rooted in its business strategy, and it continues to strive for excellence in all aspects of its operations.

As a leader in Green CRDMO, WuXi Biologics is committed to driving innovation for a healthier future. The company's green biologics solutions, such as WuXiBody™ dual-specific antibody technology, WuXiUI™ super-high-yield batch culture technology, and WuXiUP™ continuous bioreactor technology, help reduce resource consumption and carbon footprint, contributing to a more sustainable future.
WuXi Biologics' commitment to sustainability has been recognized by major ESG rating agencies. The company has been granted a "AAA" rating from MSCI ESG Ratings, awarded the distinguished Platinum Medal by EcoVadis, and recognized as an Industry and Regional Top-Rated Company by Sustainalytics. Additionally, WuXi Bio has been named to the CDP Water Security “A list” and awarded an “A-” CDP Climate Change score, demonstrating its strong performance in environmental stewardship.

In conclusion, WuXi Biologics' Platinum Medal recognition by EcoVadis for the second consecutive year underscores the company's unwavering commitment to sustainable development and responsible business practices. As a leader in Green CRDMO, WuXi Bio continues to drive innovation and contribute to a healthier, more sustainable future for all stakeholders.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios